RxDoctor Payments Data

Lori Howell

Family · Laurel, MSNPI 1366999799

Payments from drug & device makers

$9,618in general payments, 2019–2025

Across 591 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$2K
  • Johnson & Johnson$713
  • Amgen$697
  • UCB, Inc.$625
  • Sanofi$557
  • plus $3K from 20 others

What the payments were for

  • Food & beverage$9,15195%
  • Education$4675%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,618 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$184,065
Medicare patients
669
Services billed
4,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast26$130,926
Cosentyx Unoready PenSecukinumab11$125,004
Humira(Cf) PenAdalimumab14$102,455
Cosentyx Sensoready (2 Pens)Secukinumab13$99,206
Dupixent PenDupilumab24$89,479
Enbrel SureclickEtanercept12$87,916
Dupixent SyringeDupilumab12$53,123
Betamethasone Dipropionate169$5,781
Lidocaine15$2,765
Triamcinolone Acetonide75$1,611
Acitretin15$1,595
Doxycycline Hyclate57$1,496
Metronidazole29$1,458
Ketoconazole79$1,117
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip51$1,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$697$130,92626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Laurel

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →